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ABSTRACT
In this paper we aim to study an optimal insurance premium level for health-care in a determin-
istic and stochastic SIR models with migration fluxes and vaccination of population. The studied
model considers two standard SIR centres connected via links and continuous migration fluxes. The
premium is calculated using the basic equivalence principle. Even in this simple setup there are non-
intuitive results that illustrate how the premium depends on migration rates, severeness of a disease
and initial distribution of healthy and infected individuals through the centres. We investigate how
the vaccination program effects the insurance costs by comparing the savings in benefits with the
expenses for vaccination. We compare the results of deterministic and stochastic models.
Keywords optimal premium level; SIR model; epidemics.
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1 Introduction
Epidemics cause severe damage to social welfare and can result in a massive loss of working days. Many models are
developed to estimate the dynamics of epidemics, e.g. (see pioneer works Bernoulli [1760], Kermack and McKendrick
[1927], Macdonald [1957], Ross [1910] and later works Bailey [1957], Bolker and Grenfel [1995], Burton et al. [2012],
Gleißner [1988], Hethcote [1978], Lee et al. [2012]). One of the most fundamental works with strict mathematical and
medical approaches is Daley and Gani [1999]. Investigation of these models can help understanding the key points of
the phenomena and to determine the optimal vaccination strategy, which could stop the spread of the pandemic and
reduce the economical costs.
Urgent decisions are required when the epidemic starts to spread. The public health-care should provide the medi-
cine for citizens to insure they get immunity. The optimal vaccine allocation in connected SIR centres was discussed
in Chernov et al. [2019]. The vaccine might not always be free of charge. On the contrary, for an average person it
could be too expensive to afford. If a person does not agree to purchase the vaccination, he is forced to buy a man-
datory health insurance policy that covers treatment expenses and (possibly) pays a lump sum when the policyholder
becomes healthy again after disease. An insurance company collects premiums from susceptible group and covers the
health-care benefits to infected policyholders. The optimal premium level is then calculated according to the classical
equivalence principle
E[benefit outgo] = E[premium income]. (1)
In this paper we consider deterministic and stochastic SIR models with two connected centres and constant migration
fluxes. The model considers three population groups: Susceptible to a disease St, Infected It and RemovedRt persons.
The last group consist of subjects who either got an immunity and will not become ill again. The centres could
represent cities, countries, health-care facilities, etc. We calculate health-care premium level for different parameters
of model and investigate insurance costs.
Epidemic model have been proposed in different actuarial methods in Feng and Garrido [2011], Lefèvre et al. [2017].
Feng and Garrido [2011] consider constant infection and recovery rates in isolated SIR model without migration. Au-
thors present calculations of annuity premiums and annuity benefits, lump-sum benefits and death benefits. They also
propose power series solutions for evaluating the dynamic of the model. Then the premium adjustments are introduced
and the method is applied to real data sets: great plague in Eyam in 1665, SARS epidemic in Honk Kong in 2003.
In Lefèvre et al. [2017] authors consider time-continuous Markov model of epidemic spread with one centre and dif-
ferent epidemic scenarios: general and fatal epidemics, case with exponentially-dependent rates, and a single-time
change of infection rate model.
The aim of this work is to investigate the optimal health-care premium level pi in deterministic and stochastic connected
SIR centres. We consider different scenarios (different centres’ characteristics), investigate the dependence of premium
pi from the amount of vaccine available, infection rates, migration intensities. Further, we compare the result of
different scenarios for stochastic and deterministic models.
The paper is organised as follows. In Section 2 we consider deterministic SIR model and premium calculation in
this case. In Section 3 we study stochastic SIR centres and describe simulation methods by Markov chain. Section 4
is dedicated numerical simulations of deterministic and stochastic SIR models for different initial parameters and
comparing results. Conclusion and an outlook for a further work is given in Section 5.
2 Deterministic model
2.1 Connected SIR model
The classical SIR model for n centres with migration fluxes is governed by the following ODEs:
dSi
dt
= −β(Ri)SiIi −
∑
j 6=i
kij Si +
∑
j 6=i
kji Sj
dIi
dt
= β(Ri)SiIi − µ(Ri) Ii −
∑
j 6=i
lij Ii +
∑
j 6=i
lji Ij
dRi
dt
= µ(Ri) Ii
Si(0) = Si,0, Ii(0) = Ii,0, Ri(0) = Ri,0
(2)
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where i = 1, 2, . . . , n, infection rate β(Ri) and recovery (fatality) rate µ(Ri) are dependent on the number of removed
people in i-th centre; kij and lij are the migration rates of susceptible and infected groups, respectively, from i-th to
j-th centre; Si,0, Ii,0 and Ri,0 are initial numbers of susceptible, infected and removed persons. The total population
in centre i is then Ni(t) = Si(t) + Ii(t) +Ri(t). Total number of population is N(t) =
∑n
i=1 Ni(t). The analysis of
SIR model with migration is given in Sazonov et al. [2015].
Infection and recovery rates depending on the number of removed persons allow us to represent different epidemic
scenarios by choosing corresponding response to the dynamic of the epidemic. For instance, in case of fast spread-
ing disease (i.e. flue, influenza, measles) intensity of infection reduces as the number of immune persons increases,
yielding to decreasing β(Ri). On the other hand, in case of sexually transmitted diseases, as the efficiency of treat-
ment methods improves, people are tending to have riskier sexual connections, leading to increasing function β(Ri).
Moreover, treatment of patients implies examination of the disease, following increasing function µ(Ri). On contrary,
if a disease is more persistent as the number of infected people increases (i.e. number of removed goes down), then
the function µ(Ri) is decreasing.
Usually, when an infected individual is transferred into removed class, he is considered to get an immunity and total
number of the population remains unchanged. Hence, the natural assumption is β(Ri) ≡ βi = α/Ni. In case of
fatal epidemic (see Gleißner [1988]) the removed group consist of dead people, and the natural assumption is to let
β(Ri) ≡ α/(Ni − Ri). So, the dependence of the rates from number of removals is very diverse an can describe
different scenarios on practice. In this case, the basic reproduction number is defined as R0 = α/µ.
Another key object of the model is the time moment T when the epidemic stops. It is widely known that nontrivial
solutions of (2) have exponential character. Therefore, we can never obtain pure zero number of infectives by integrat-
ing the system. It is natural to say that if there are less infectives then a certain value, then the epidemic is assumed to
be suppressed. We therefore set the threshold percentage θ of living population at time T . In case of general epidemic
define T as
T = inf

t :
∑
i=1,...,n
Ii(t) < θ ·N(t)

 , (3)
and in case of fatal epidemic as follows:
T = inf

t :
∑
i=1,...,n
Ii(t) < θ ·
(
N(t)−
n∑
i=1
Ri(t)
)
 . (4)
2.2 Infectivity and susceptibility times
One of the key functionals is
Ai(T ) =
∫ T
0
Ii(t) dt, i = 1, . . . , n,
which describes the total number of lost working days during the epidemic in i-th centre. This functional also allows
us to measure the medical expenses for treating infected persons.
Since we are interested in total number of lost working days in the network, we sum over i and define
AT =
n∑
i=1
Ai(T ) =
n∑
i=1
∫ T
0
Ii(t) dt. (5)
During the epidemic, an insurance company collects premiums from healthy individuals with some rate (will be
introduced in Sect. 2.3). The total exposure to premiums of all susceptible persons at i-th centre equals
Bi(T ) =
∫ T
0
Si(t) dt, i = 1, . . . , n.
By summing over i, we define
BT =
n∑
i=1
Bi(T ) =
n∑
i=1
∫ T
0
Si(t) dt. (6)
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2.3 Premium calculation
A premium is calculated according to the standard equivalence principle (1). On the liability side, the benefits are
payed by insurance company to infected persons with constant intensity c1. For a person transferred to the removed
group (i.e. got the immunity or has died due to a fatal disease) the company pays a lump sum c2 to every beneficiary.
In line with Lefèvre et al. [2017], we assume that all claims are settled at time T when the epidemic is extinct.
We assume that the insurance company has a permission to resell the vaccine to the population. The amount of vaccine
V could be bought from other centre (i.e. city, country), ordered to be developed / manufactured, etc. In any case,
there is a liability part and we let c3 be a cost of one vaccine unit. Therefore, the expected liability is
E[benefit outgo] = c1AT + c2
n∑
i=1
Ri(T ) + c3V . (7)
On the other hand, the insurance company collects constant premiums pi from susceptible population until they become
ill or the epidemic has ended. Also, we let Vsold be a number of sold vaccine. So, the expected income of the company
is
E[income] = piBT + c4Vsold. (8)
By equivalence principle (1) and expressions (7) – (8) we get
pi =
1
BT
(
c1AT + c2
n∑
i=1
Ri(T ) + c3V − c4Vsold
)
. (9)
We also consider a constant time-continuous discounting factor δ to calculate the present value of benefits and incomes.
Therefore, we complete formulae (5) and (6) as follows:
Aδ,T =
n∑
i=1
∫ T
0
exp(−δt) Ii(t) dt
Bδ,T =
n∑
i=1
∫ T
0
exp(−δt)Si(t) dt
(10)
In the end, we also enhance the premium calculation as
piδ =
1
Bδ,T
(
c1Aδ,T + c2 exp(−δT )
n∑
i=1
Ri(T ) + c3V − c4Vsold
)
. (11)
2.4 Optimal vaccine allocation
Once the epidemic starts and the company possesses vaccine amount V , it is important to wisely allocate the vaccine
in the centres. We assume that the vaccination is instantaneous and people prefer to vaccinate rather than risk their
health. Let wi be the shares of vaccine stock V allocated in i-th centre, i = 1, . . . , n. In Chernov et al. [2019] it is
shown that the best vaccination time is t = 0, since any delay in vaccination let the infection to spread. Therefore, the
SIR model (2) with vaccine allocation (w1, . . . , wn) : wi ≥ 0, w1 + . . .+ wn = 1 takes the form
dSi
dt
= −β(Ri)SiIi −
∑
j 6=i
ki,j Si +
∑
j 6=i
kj,i Sj −min{Si,0, wiV}δ(t),
dIi
dt
= β(Ri)SiIi − µ(Ri) Ii −
∑
j 6=i
li,j Ii +
∑
j 6=i
lj,i Ij ,
dRi
dt
= µ(Ri) Ii,
Si(0) = Si,0, Ii(0) = Ii,0, Ri(0) = Ri,0,
(12)
where δ(t) is Dirac delta function.
4
A PREPRINT - 14TH OCTOBER 2019
One natural way to optimally allocate the vaccine is to minimise the resulting premium (9) or (11). Since the health-
care is assumed to be mandatory, we would like to reduce the premium payed by susceptibles as much as possible.
More formally, for given vaccine stock and model parameters we get
pi∗ = min
(w1,...,wn):wi≥0,
w1+...+wn=1
1
BT
(
c1AT + c2
n∑
i=1
Ri(T ) + c3V − c4Vsold
)
. (13)
Allocation (w1, . . . , wn) affects the initial number of susceptible persons, which affect AT , BT and Ri(T ). Here we
allow cases when the vaccine amount is not fully utilised. It is clearly not optimal to “waste” vaccine, but those cases
are negligible. Therefore, the vaccine amount V and the vaccine sold Vsold are not always the same.
Alternatively, we could set as a goal to keep low epidemic costs, i.e. have as less lost working days as possible.
Therefore, optimal vaccine allocation could be such that the functionalAT is minimised:
A∗T = min
(w1,...,wn):wi≥0,
w1+...+wn=1
n∑
i=1
∫ T
0
Ii(t) dt. (14)
It is interesting to see the relation between two “optimality" points of view. Both have sensible reasons of treating
epidemic – first is financially oriented, whilst the second prevents population from being ill.
3 Stochastic model
As in previous chapters, we denote number of susceptible persons at time t as S(t), infected persons – I(t) and
recovered / removed persons – R(t). Here the main interest is to model the infection spread among population
assuming small number of initially infected persons.
If number of infectives is small, the infection can get naturally suppressed, not causing any epidemic outbreak. A
stochastic model is generally devoted for such cases, whereas deterministic differential models describe evolution of
epidemic in high population with large number of infected individuals. The algorithm of merging two approaches is
proposed in Sazonov et al. [2011].
All stochastic models are considered to have discrete state space in continuous time. Also, models have Markov
property, i.e. probability of transition from one state to other does not depend on history. These assumptions are
natural because in real epidemics the number of people getting infection only depends on the number of contacts
with infected persons. We do not study cases when a disease can infect people from other sources (water, air breeze,
unsanitary conditions, intentional release of a disease, etc.). Similarly, recovery / death probability only depends on
the host of the infection.
3.1 Markov chain for one centre
In case of one centre model the transition probabilities of standard stochastic model with constant coefficients β and
µ are presented in Table 1.
We denote the time of j-th jump (switch of state) as tj . Corresponding waiting time (i.e. time between j − 1-th and
j-th jumps) as sj .
Table 1: Transition probabilities of time continuous Markov chain in case of one centre.
Event Rate Condition
S → S − 1, I → I + 1 βSI S > 0
I → I − 1, R→ R+ 1 µI I > 0
Absorbing state 0 I = 0
The final time of epidemic is a random variable that depends on the chain evolution. We define the end of epidemic as
T = inf{t : I(t) = 0}. (15)
Simulation algorithm is presented in Algorithm 1. The general approach is to calculate all transition rates at time
tj and simulate the waiting time sj (line 4) as exponential random variable with inverse mean equal to sum of all
5
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rates. Then generate a standard uniform random variable uj (line 6) to decide which event took place. Calculate the
probability of an event as its rate divided by sum of all rates (line 7). Finally, choose a corresponding event (lines
8–12).
Algorithm 1: Markov chain simulation for one centre
Result: T, S(T ), I(T ), R(T )
1 set S = S0, I = I0, R = 0, t0 = 0, j = 1;
2 calculate N = S + I +R;
3 while I > 0 do
4 generate sj ∼ Exp(βSI + µI);
5 set tj = tj−1 + sj ;
6 generate uj ∼ Unif(0, 1);
7 set probabilities p1 =
βSI
βSI+µI and p2 =
µI
βSI+µI ;
8 if uj < p1 then
9 set S = S − 1, I = I + 1;
10 else
11 set I = I − 1, R = R+ 1;
12 end
13 j ← j + 1
14 end
15 set T = tj
3.2 Markov chain for multiple centres
Here we consider a stochastic model for epidemic in multiple centres. Denote a number of susceptibles in i-th centre
at time t as Si(t), infectives – Ii(t) and recovered / removed – Ri(t) for i = 1, . . . , n. We let coefficients β(Ri) and
µ(Ri) now be dependent on the number of removals (see Sect. 2.1). Then the transition rates for i, j = 1 . . . n are
presented in Table 2. The end of epidemic is defined as
T = inf
{
t :
n∑
i=1
Ii(t) = 0
}
.
Table 2: Transition probabilities of time continuous Markov chain in case of multiple centres
Event Rate Condition
Si → Si − 1, Ii → Ii + 1 β(Ri)SiIi Si > 0
Ii → Ii − 1, Ri → Ri + 1 µ(Ri)Ii Ii > 0
Si → Si − 1, Sj → Sj + 1 kijSi Si > 0, i 6= j
Ii → Ii − 1, Ij → Ij + 1 kijIi Ii > 0, i 6= j
Absorbing state 0
∑n
i=1 Ii = 0
The simulation algorithm of one Markov chain for n centres is similar to Algorithm 1. However, here the dimension of
one state is 3n−1, where we have three numbers for susceptible-infected-recovered triplet and n centres with constant
population throughout the network. Latter reduces the dimension by one.
3.3 Vaccination in the random setup
Introduction of additional centres makes definition of optimal vaccine allocation more complicated. We calculate the
health-care premium according to the equivalence principle (1). However, unlike (9), the formula for premium in
stochastic model has the form
pi =
1
E[BT ]
(
c1E[AT ] + c2
n∑
i=1
E[Ri(T )] + c3V − c4Vsold
)
, (16)
and discounted premium is
piδ =
1
E[Bδ,T ]
(
c1E[Aδ,T ] + c2
n∑
i=1
E[exp(−δT )Ri(T )] + c3V − c4Vsold
)
. (17)
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Unlike deterministic model (12) with vaccine stock V , in stochastic setup we need to clarify what is optimal vaccine
allocation with integers (w1, . . . , wn) : wi ≥ 0,
∑n
i=1 wi = V . In stochastic model we let V ≡ V Therefore, we
apply the following procedure:
Algorithm 2: Calculation of optimal vaccine allocation for stochastic model for n centres
input :amount of vaccine V ,
minimisation optionQ ∈ {pi, piδ, AT , Aδ,T },
number of simulationsNsim
Result: w∗ = (w1, w2, . . . , wn)
1 for all possible w = (w1, w2, . . . , wn) : wi ≥ 0,
∑n
i=1 wi = V do
2 simulate Nsim Markov Chains, computingQk(w), k = 1, . . .Nsim;
3 calculate averageQ =
∑Nsim
k=1 Qk(w);
4 end
5 choose w∗ = (w1, w2, . . . , wn) such that Q(w) is minimal;
6 i.e. w∗ = argminwQ(w) ;
The idea of Algorithm 2 is to consider all possible vaccine allocations and simulate Nsim Markov chains for each
allocation (i.e. performMonte Carlo method). Then we choose such allocationw∗ = (w1, w2, . . . , wn) that minimises
the desired functional (resulting health-care premium pi, lost working days AT , or corresponding discounted values).
After computing optimal vaccine allocationw∗, we calculate corresponding optimal premium pi∗, pi∗δ , pi(A
∗
T ), pi(Aδ,T ),
i.e. use formulae (16) – (17).
4 Numerical experiments
Let us consider models (2) and (3.2) with two centres. Fix the removal rate µ(Ri) ≡ µ = 1, and consider functions
β(Ri) for different scenarios (general and fatal epidemic), and vary basic reproduction number to investigate the
optimal premiums. Let initial number of removed persons be Ri,0 = 0 for i = 1, 2.
In line with Lefèvre et al. [2017], let the constant payment intensity c1 = 1 and a lump sum c2 = 2. We let the cost
of one vaccine unit V be c3 = 4. The selling price of one vaccine unit c4 is usually assumed to be higher than the unit
cost.
In all figures (in deterministic section) horizontal axis corresponds to the vaccine amount required to vaccinate V
percents of susceptible individuals, i.e. V = V S. For example, if S = S1 + S2 = 100, then V = 0.2 means that the
company can vaccinate 20% of susceptibles, i.e. V = 20 individuals. We only consider V ∈ [0, 0.5] since it becomes
extremely hard to vaccinate more than a half of population. Moreover, since people have a choice to buy the vaccine
or not, it becomes less likely that the company can sell entire vaccine stock.
General epidemic. In general epidemic setup we assume that after being infected a person gets immunity and will
not get ill for the rest of epidemic period. Therefore, the number of total population remains constant and a natural
assumption is to let β(Ri) = α/Ni.
Fatal epidemic. Here we assume that the disease is fatal and removed class corresponds to the number of dead people.
In this case the population is decreasing over time and a natural assumption is to let β(Ri) = α/(Ni − Ri), see
Gleißner [1988].
In both epidemic options the basic reproduction number becomesR0 ≡
α
µ . We investigate some cases of R0 ∈ [2, 12]
that correspond to reproduction numbers of different diseases. Further, we investigate the optimal premium level with
and without discounting factor δ = ln 1.01.
4.1 Deterministic model
Assume that the end of epidemic T is the moment when the total number of infectives is smaller than θ = 0.5% of
living population at time T , i.e. use formulae (3) – (4).
4.1.1 Basic deterministic scenario
Here we consider a basic scenario, in which we have similar migration fluxes and both centres are equivalent. We let
the initial populations be Si,0 = 100, Ii,0 = 10, and let migration flows be k1,2 = k2,1 = 0.5 and l1,2 = l1,2 = 0.1.
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(a) General epidemic, premium minimisation
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(b) General epidemic, AT minimisation
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(c) Fatal epidemic, premium minimisation
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2
(d) Fatal epidemic, AT minimisation
Figure 1: Premium level for general and fatal epidemics in basic scenario for Ebola, influenza. Dashed line – corres-
ponding premium with discounting factor δ = ln 1.01. Basic reproduction numberR0 = 2.
This scenario represents the simplest case when both centres are the same. The interest here is to investigate the
vaccination options and detect some noticeable dependencies.
For infections that have low basic reproduction number (see Fig. 1) both “optimality” approaches have similar results
(compare Fig. 1a with Fig. 1b, and Fig. 1c with Fig. 1d). The resulting premium depends on selling price c4. On Fig. 1,
2 and 3 we clearly see that increase in selling price c4 result in reducing premium level.
From Fig. 1 we see that the discounted premium (11) is lower than the premium without discount (9). In general
(Fig. 1a–1b) and fatal (Fig. 1c–1d) epidemics discounted premiums noticeably differ from non-discounted.
Due to concavity of the premium level (Fig. 1) with respect to vaccine amount, it is better either not to purchase any
vaccine at all, or alternatively purchase as much as possible, if the company is confident that it will be sold to the
population at price c4.
In case of more serious diseases (see Fig. 2) the difference between two “optimality” approaches is only seen in case
of general epidemic (Fig. 2a–2b) for vaccine amount close to 50% of susceptibles. This is the point when vaccine
allocation for lost working days minimisation problem (equations (13)-(14)) switches strategy from putting all vaccine
available into one centre to dividing equally between two centres (see Chernov et al. [2019]). For larger V the effect
of vaccination is not that noticeable. Therefore, the vaccine becomes not self-sustaining.
In case of fatal epidemic (Fig. 2c–2d) we do not see the same behaviour. According to small difference between
discounted and non-discounted premium levels, the epidemic is taking over, so that all susceptible persons die quite
fast, and only vaccinated people pay money for the vaccine. Very similar results are for severe infections, see Fig. 3.
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(a) General epidemic, premium minimisation
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(b) General epidemic, AT minimisation
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(c) Fatal epidemic, premium minimisation
0 0.1 0.2 0.3 0.4 0.5
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5
5.5
(d) Fatal epidemic, AT minimisation
Figure 2: Premium level for general and fatal epidemics in basic scenario for diphtheria, mumps, polio, smallpox.
Dashed line – corresponding premium with discounting factor δ = ln 1.01. Basic reproduction numberR0 = 6.
4.1.2 Health-centre
Assume that the epidemic has started in two centres, but only one of them has a medical facility that can cure the
disease effectively. In this case, infected persons from the second centre are willing to get to the first centre to cure the
disease, while infected persons from the first centre stay at home. We also assume that the second centre has a medical
institution, but it is not that effective.
It is natural to assume that the first centre, which has the medical facility, is technologically more advanced and has
higher population. Let the population of the first centre be S1,0 = 5000 and I1,0 = 800, and the population of the
second centre be S2,0 = 1000 and I2,0 = 200.
In this scenario, we assume that susceptible groups in both centres are travelling with rates k12 = 0.1 and k21 = 0.15,
which represent the well-being of both centres. On contrary, the infected group in the first centre almost do not travel
l12 = 0.05, while infectives from the second centre are coming to the health-centre with rate l21 = 2.5.
We also assume that a health-centre is affecting curing time, while the infection rate of a disease remains the same
(basic reproduction number is unchanged with µ = 1). Hence, for a general epidemic we let µ1 = 2 and µ2 = −0.9
(see (18)), which corresponds to faster curing at the first centre and lower recovery rate at the second. In case of fatal
epidemic, the first centre provide better treatment, so that a person lives longer, and it is opposite at the second centre.
Therefore, for a fatal epidemic we consider symmetric case: µ1 = −0.9 and µ2 = 2.
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(a) General epidemic, premium minimisation
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(b) General epidemic, AT minimisation
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(c) Fatal epidemic, premium minimisation
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(d) Fatal epidemic, AT minimisation
Figure 3: Premium level for general and fatal epidemics in basic scenario for malaria and measles. Dashed line –
corresponding premium with discounting factor δ = ln 1.01. Basic reproduction number R0 = 12.
Table 3: Optimal vaccine share in health-centre scenario harmful R0 = 6 and severe R0 = 12 diseases for fatal
epidemics.
c4 3 3.5 4 4.5
V ∗ 0.14 0.16 0.17 0.18
dSi
dt
= −β(Ri)SiIi −
∑
j 6=i
kij Si +
∑
j 6=i
kji Sj
dIi
dt
= β(Ri)SiIi − (µ+ µi) Ii −
∑
j 6=i
lij Ii +
∑
j 6=i
lji Ij
dRi
dt
= (µ+ µi) Ii
Si(0) = Si,0, Ii(0) = Ii,0, Ri(0) = Ri,0
(18)
Fig. 4, 5 and 6 show results for mild, harmful and severe diseases, correspondingly. In general epidemic setup the
results are completely different comparing to the basic scenario 4.1.1. One of the main differences is the shape of the
graphs – for smaller selling prices c4 premiums in basic scenario 4.1.1 mostly have concave shape, while correspond-
ing graphs in health-centre scenario 4.1.2 have convex shape. Moreover, here we see characteristic threshold (local
minimum of premium) for all reproduction numbers.
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Figure 4: Premium level for general and fatal epidemics in health-centre scenario for Ebola, influenza. Dashed line –
corresponding premium with discounting factor δ = ln 1.01. Basic reproduction number R0 = 2.
In case of mild diseases (see Fig. 4) there is a noticeable vaccine share V ∗ ≈ 0.18, which corresponds to local
minimum of both “optimal” premiums for fatal epidemics (see Fig. 4c and 4d) and less distinct local minimum for
general epidemics (see Fig. 4a and 4b). Therefore, for slowly spreading infections there is a universal strategy of
vaccinating 18% of susceptible population – fully vaccinate the second centre (i.e. 1000 susceptibles) and partly
vaccinate the health-centre (i.e. 80 individuals).
Fig. 5 shows results for harmful diseases. As it is seen in Fig. 5a and 5b, there is a more sharp minimum of both
“optimal” premiums in case of general epidemic, which occurs in V ∗ ≈ 0.18 uniformly with respect to selling price
c4. Hence, for general epidemic of infection with basic reproduction number R0 = 6 it is enough to vaccinate 18%
of population, allocating the vaccine in the same way: 80 individuals in the first centre and 1000 – in the second. The
selling price should be decided such that the population can afford to buy it (i.e. if c4 is too high, people might prefer
to buy a health-care policy instead of vaccine, which will shift the local minimum point).
For fatal diseases (see Fig. 5c, 5d, 6c and 6d) the local minimum point is not that distinct as in Fig. 4c and 4d, and
depends on selling price c4. Particularly, for both “optimal” premiums the vaccine shares V
∗ are presented in Table 3.
4.2 Stochastic model
In this section we abandon notation V and let V denote the available vaccine stock. It is a natural number (including
zero), since the stochastic model concentrates on particular individuals, so the vaccine amount cannot be a real number.
According to proposed Algorithm 2 for computation of optimal vaccine allocation, for small vaccine number V we
need to look over small number of possible allocations. In fact, in case of two centres the number NV of all possible
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Figure 5: Premium level for general and fatal epidemics in basic scenario for diphtheria, mumps, polio, smallpox.
Dashed line – corresponding premium with discounting factor δ = ln 1.01. Basic reproduction numberR0 = 6.
allocations of vaccine amount V is
NV = V + 1
Therefore, we can afford to run a lot of Monte Carlo simulations Nsim for small V , and we try to keep Nsim low for
larger vaccine amounts. So, we propose the following number of simulations depending on V :
Nsim = ⌈100 · (1 + 29e
−V/5)⌉.
This will allow us to calculate average premiums with higher accuracy (i.e. with lower variance) for lower V , while
maintaining the precision for higher vaccine stocks.
In all graphs in this section we present premiums with 95% confidence intervals
pi∗ ± z0.975
√
var(pi∗)
Nsim
,
where z0.975 is quantile of standard normal distribution and var(pi
∗) is calculated during Algorithm 2 as sample
variance. This form of confidence interval follows directly from Monte Carlo estimator properties.
Stochastic model is generally used to describe the infection spread throughout the population for small numbers of
infected persons. The key point is that the infection can be extinct, i.e. get naturally suppressed, not causing any
outbreak. For this reason we complement Algorithm 2 with calculation of average number of extinct epidemics. For
this cause we set percentage η = 0.1 of population, and say that there was no outbreak, if maximal number of infected
individuals at any point of time is smaller than 10% of total susceptible population at time t = 0:
max
0≤t≤T
2∑
i=1
Ii(t) < η · (S1,0 + S2,0).
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Figure 6: Premium level for general and fatal epidemics in basic scenario for malaria and measles. Dashed line –
corresponding premium with discounting factor δ = ln 1.01. Basic reproduction number R0 = 12.
In general, many computationally expensive simulations should be performed to obtain precise result, which is usually
done on supercomputers. Therefore, the following results are not reliable enough to conclude anything about optimal
vaccine allocation and precise premium calculations. However, they provide a satisfactory behaviour of premium
dependencies.
4.2.1 Basic stochastic scenario
Here we consider a basic scenario that is analogous to deterministic case Sect. 4.1.1. In line with Lefèvre et al. [2017],
we let initial number of susceptible individuals be Si,0 = 30, however, we consider less infected people: Ii,0 = 1 for
i = 1, 2. Further, we let migration fluxes be k12 = k21 = 0.1 and l12 = l21 = 0.05.
In stochastic model for minor diseases in general epidemic case (see Fig. 7) all premium levels are increasing for
selling prices c4 less than vaccine cost c3 = 4. If epidemic is fatal, the premium level becomes decreasing for c4 > c3.
During numerical simulations we assess number of epidemics that are naturally suppressed and calculate their fractions,
see Table 4 for mild diseases (R0 = 2), Table 5 for harmful diseases (R0 = 6) and Table 6 for severe diseases
(R0 = 12).
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Figure 7: Premium level for general and fatal epidemics in basic stochastic scenario for Ebola, influenza. Dashed line
– corresponding premium with discounting factor δ = ln 1.01. Shaded area – 95% confidence interval of pi. Basic
reproduction numberR0 = 2.
Table 4: Basic scenario. Extinct epidemic rates for mild diseases R0 = 2.
Minimisation
V = 0 V = 7 V = 15 V = 30
General Fatal General Fatal General Fatal General Fatal
pi 30.2% 26.0% 32.1% 28.7% 32.2% 35.9% 37.0% 54.6%
AT 30.2% 26.0% 32.1% 28.7% 32.2% 36.7% 55.6% 56.5%
Table 4 shows that even when we do not vaccinate the population, there is still relatively high chance (30.2% in general
and 26% in fatal case) to surpass the infection. When we vaccinate half of the population, i.e. V = 30, in case of
fatal epidemic both “optimality” options lead to similar extinction probability. However, if the infection is not fatal,
the premium minimisation problem (16) leads to considerably lower chances or suppressing the infection, while the
minimisation of lost working days still provides high escaping chance. The first option happens because the insurance
company tries to maintain the epidemic being active in order to collect premiums from susceptibles by allocating
vaccine evenly between centres. In this case, the epidemic has higher chance to outbreak than in case, when one centre
is completely vaccinated.
Note that some sharp peaks (e.g. Fig. 7d) are rather due to poor number of simulations, rather than specifics of certain
vaccine allocation (statement supported by high variance, i.e. big confidence interval).
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Table 5: Basic scenario. Extinct epidemic rates for harmful diseases R0 = 6.
Minimisation
V = 0 V = 7 V = 15 V = 30
General Fatal General Fatal General Fatal General Fatal
pi 2.3% 2.3% 3.3% 3.2% 3.4% 3.6% 14.0% 15.0%
AT 2.3% 2.3% 3.3% 3.6% 3.4% 3.8% 14.0% 15.0%
Table 6: Basic scenario. Extinct epidemic rates for severe diseases R0 = 12.
Minimisation
V = 0 V = 7 V = 15 V = 30
General Fatal General Fatal General Fatal General Fatal
pi 0.5% 1.2% 0.7% 0.8% 0.6% 0.9% 6.3% 6.5%
AT 0.5% 1.2% 0.7% 0.8% 0.8% 0.9% 6.3% 6.5%
For harmful diseases with reproduction number R0 = 6 in non-fatal case there is characteristic minimum for both
premiums at point V = 10, after which (in average) the premiums start to increase. In Fig. 8c there is another example
of poor stochastic simulation results.
Usually, for severe diseases most of the population becomes infected, therefore there is almost no difference between
premiums in both “optimality” approaches. We can see on Fig. 9 that the behaviour of premiums is similar to mild
disease case (see. Fig 7) – they are increasing for small selling prices c4, and decreasing as selling prices becomes
higher than a certain threshold. However, the case of harmful diseases (see Fig. 8) has more distinct vaccine amount
V ≈ 10 when the premium has local minimum.
4.2.2 Big and small centres
In this scenario we consider two cities, that resemble health-centre scenario, considered in Sect. 4.1.2. Here we assume
that we have a big centre with treatment facility, and a small centre with poor treatment. All infected persons try to
migrate to the big centre, while infected in the first centre generally stay at home. Susceptible group is travelling as
usual.
We define initial number of susceptibles as S1,0 = 50 and S2,0 = 10, and infectives as I1,0 = 2, I2,0 = 1. Migration
fluxes are k12 = 0.1, k21 = 0.15, l12 = 0.05 and l21 = 2.5. Similarly to Sect. 4.1.2, in non-fatal case we let treatment
effect in the first centre be µ1 = 2 (µ1 = −0.9 in case of fatal case), and mistreatment in the second centre be
µ2 = −0.9 (µ2 = 2 in fatal case). The natural immunisation is µ(Ri) = 1.
Fig. 10 shows the dependence of premiums from vaccine stock for the health-centre scenario in stochastic model for
mild diseases. In non-fatal case (see Fig. 10a and 10b) the number of simulations is sufficient to provide narrow
confidence intervals. In Fig. 10b after a threshold V = 10 there is a switch of strategy from vaccinating the second
centre to vaccination of both. Due to randomness of simulations, the minimisation of function AT becomes less
reliable. When vaccine amount is less than 10, the behaviour is similar to Fig. 10a, where we observe precise steady
grow (decline) of premium, similar to deterministic results.
Table 7: Big and small centres. Extinct epidemic rates for mild diseases R0 = 2.
Minimisation
V = 0 V = 7 V = 15 V = 30
General Fatal General Fatal General Fatal General Fatal
pi 65.1% 0.3% 70.4% 0.1% 79.1% 0.2% 80.9% 0.2%
AT 65.1% 0.3% 70.4% 0.3% 79.3% 0.3% 84.2% 0.2%
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Figure 8: Premium level for general and fatal epidemics in basic stochastic scenario for diphtheria, mumps, polio,
smallpox. Dashed line – corresponding premium with discounting factor δ = ln 1.01. Shaded area – 95% confidence
interval of pi. Basic reproduction number R0 = 6.
Table 8: Big and small centres. Extinct epidemic rates for harmful diseases R0 = 6.
Minimisation
V = 0 V = 7 V = 15 V = 30
General Fatal General Fatal General Fatal General Fatal
pi 6.4% 0% 7.0% ≈ 0% 10.6% ≈ 0% 15.9% ≈ 0%
AT 6.4% 0% 7.0% ≈ 0% 10.4% ≈ 0% 15.9% ≈ 0%
For harmful diseases (see Fig. 11) in non-fatal case we see a more or less distinct area 10 ≤ V ≤ 12, where the
vaccine is directed to the second centre (vaccinating all susceptibles), and some persons from the first centre receive
vaccine too. Here we still see that both “optimality” options provide the same premium levels. From Fig. 11a and 11b
we see that it is not important which selling price to choose, the optimal premium will remain almost the same, while
we have small number of vaccine. The difference only comes to play when we start to divide vaccine between two
centres.
A table of extinct epidemics in stochastic health-centre scenario for severe diseases is omitted due to extremely rare
escaping events. Even in non-fatal epidemic case for V = 30 the suppression of the infection happens only in 1 out of
100 simulations.
Fig. 12 for severe diseases show very similar results (accurate to constant) compared to harmful diseases, see Fig. 11.
In particular, we have the area 10 ≤ V ≤ 12 when both “optimal” premiums are minimal, which corresponds to full
vaccination of the second centre and (if there is vaccine left) the remaining part is directed to the first centre. For low
vaccine amount there is almost no difference between premium levels with respect to selling price c4.
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Figure 9: Premium level for general and fatal epidemics in basic stochastic scenario for malaria and measles. Dashed
line – corresponding premium with discounting factor δ = ln 1.01. Shaded area – 95% confidence interval of pi. Basic
reproduction numberR0 = 12.
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Figure 10: Premium level for general and fatal epidemics in stochastic health-care scenario for Ebola, influenza.
Dashed line – corresponding premium with discounting factor δ = ln 1.01. Shaded area – 95% confidence interval of
pi. Basic reproduction numberR0 = 2.
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Figure 11: Premium level for general and fatal epidemics in stochastic health-care scenario for diphtheria, mumps,
polio, smallpox. Dashed line – corresponding premium with discounting factor δ = ln 1.01. Shaded area – 95%
confidence interval of pi. Basic reproduction numberR0 = 6.
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Figure 12: Premium level for general and fatal epidemics in stochastic health-centre scenario for malaria and measles.
Dashed line – corresponding premium with discounting factor δ = ln 1.01. Shaded area – 95% confidence interval of
pi. Basic reproduction numberR0 = 12.
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5 Conclusions
There is a major theory that supports all models, including analysis of the solutions and dependencies from initial
conditions. In general, all models are supposed to study individuals with certain probabilities of passing/receiving the
infection, migration, immunisation, etc. However, the theory shows that solution of stochastic model with a lot of
time steps is approaching the solution of differential problem with relatively large number of initially infected persons.
At the same time, when the number of infected individuals is small, the epidemic has high probability to be naturally
suppressed, which is only possible in stochastic model.
In this work we concentrate on the simplest SIR model with two centres and migration fluxes. We study both dif-
ferential and stochastic models in different "what-if" scenarios. We assume that there is a vaccine that should be
optimally distributed among the centres. Individuals who did not get the vaccine must buy a mandatory health-care
policy that covers all expenses of treatment in case of getting infected. Taking into account the dynamics of epidemic,
we calculate the health-care premium according to equivalence principle.
We propose two measures of “optimality” – one being financially driven, while the second aims to maintain the
population healthy. Generally, both approaches result in the same premium level, however, vaccine allocation strategies
are different. If both measures gave different results, it would necessary to consider a linear combination of two with
proper coefficients.
In the SIR model we also studied fatal and general (non-fatal) epidemics. In the model after being infected a person
is transformed into removed (recovered) group. While it is natural in case of non-fatal epidemic, this assumption
drastically restricts the number of infections that could be described by fatal SIR model. Therefore, the results of
fatal epidemics are very narrow-focused. Moreover, the proposed minimisation of functional AT , see (14), is not the
best option for fatal epidemics, because it does not account for number of deaths. Hence, an improvement should be
considered, for example, in a form
A∗T = min
(w1,...,wn):wi≥0,
w1+...+wn=1
n∑
i=1
∫ T
0
[α1Ii(t) + α2Ri(t)] dt, αi ∈ R+. (19)
That way, not only we try to reduce the number of lost working days, but also the total exposure to death.
The results of numerical integration 4.1 and stochastic simulations 4.2 show some interesting results of vaccine alloc-
ation strategies and resulting premiums. The calculations are made for infections with different hostility levels. The
main concern here is to investigate strategies under low vaccine stock.
Future works could consider more detailed cases, like
• non-fatal epidemic, individuals may choose to vaccinate depending on the vaccine selling price c4;
• fatal epidemic, SIRS model, minimisation of enhanced functional (19);
• non-instant vaccination (i.e. it take time to vaccinate people, increasing exposure to a disease).
Also, most of the models’ parameters should be specified by experts, providing more accurate and applicable results.
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